Orchid's Q2 Revenue Slides 14 Percent on Lower Forensic Demand | GenomeWeb
NEW YORK (GenomeWeb News) – Orchid Cellmark today reported a 14-percent decline in revenues amid mounting losses for the second quarter.
Total revenues for the second quarter fell to $13.6 million from $15.8 million in the year-ago period. Orchid said that the decline in revenues was largely due to lower US government paternity and forensic casework and lower overall UK forensic service revenues.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.